CDSCO Revokes Registration of FatX Solution Over Unverified Fat-Dissolving Claims

NEW DELHI — India’s apex drug regulatory body, the Central Drugs Standard Control Organization (CDSCO), has formally revoked the registration of FatX Solution, a popular injectable cosmetic treatment, following aggressive and unverified claims regarding its fat-dissolving capabilities. The regulatory intervention marks a significant enforcement action aimed at curbing deceptive marketing practices within the aesthetic medicine sector.

Controversy surrounding the product escalated as federal inspectors noted that the formulation was being marketed with medical and therapeutic promises that exceeded its approved cosmetic classification. Industry analysts point out that non-surgical fat-dissolving treatments have witnessed a surge in consumer demand, prompting regulatory bodies to closely monitor manufacturers who bypass stringent clinical validation protocols to promote localized weight loss.

According to investigative reports published by the Times of India, federal health officials determined that the promotional strategies employed by distributors of FatX Solution posed potential risks to public safety by misleading consumers about the physiological impacts of the substance. Medical experts have repeatedly cautioned that unapproved lipolytic injections can trigger severe adverse dermatological reactions, systemic inflammation, and unpredictable tissue necrosis if administered without proper oversight.

In the wake of this cancellation, regulatory authorities are expected to launch a wider inspection drive targeting similar aesthetic injectables distributed across domestic markets. Legal and industry observers anticipate that manufacturers of cosmetic solutions will face heightened compliance mandates, forcing companies to substantiate all marketing claims with rigorous scientific data before securing commercial clearance in India.